-
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
•
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business Division (EBD), is leaving the company to pursue external opportunities, with her last day set for March 3. Dr. Christine Zhou Xia Ping, Novo’s senior vice president and president of Region China, will assume the…
-
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
•
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015, a molecular glue product, for clinical studies in hematological and solid tumors with RAS mutations. The approval follows positive preclinical data and a strategic licensing deal with U.S.-based Erasca, Inc. Drug ProfileJYP0015, a novel pan-RAS…
-
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has received clinical trial approval from China’s National Medical Products Administration (NMPA) for asthma. The approval follows similar clearances in New Zealand (October 2024) and the U.S. (January 2025), positioning the drug for global development. Clinical…
-
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a strategic partnership with Shanghai-based Best Covered, a technology company specializing in Alzheimer’s disease (AD). The collaboration aims to enhance early screening, precise testing, personalized intervention, and digital management of AD. Partnership GoalsThe two companies will…
-
Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
•
Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to exercise partial subscription rights to acquire the remaining equity interests in Nanjing Kainite Medical Technology Co., Ltd from Nanjing Fund and Shanghai Hongsheng Intelligent Technology Co., Ltd. Acquisition DetailsAccording to the latest agreement, the acquisition…
-
Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
•
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to its lead candidate, CBP-1019, for the treatment of recurrent endometrial cancer in patients who have received prior platinum-based chemotherapy. FDA Designation and Drug ProfileThe…
-
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
•
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb data for duvakitug, their experimental monoclonal antibody targeting TL1A, at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress. The RELIEVE UCCD study evaluated the drug in moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD),…
-
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
•
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical study of its 3D-printed drug product D23, a budesonide ileum-targeted tablet designed to treat IgA nephropathy (IgAN). The study highlights the drug’s precise intestinal targeting and efficacy in addressing the root cause of the disease.…
-
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
•
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase III ASTRO study of its Tremfya (guselkumab) subcutaneous (SC) induction therapy for adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO). The data…
-
MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval
•
Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for its AnchorMan left atrial appendage (LAA) occluder system and its guidance system, marking a significant milestone for the China-based medical device company. The approval paves the way for the commercialization of the device in Europe.…
-
AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the U.S. Food and Drug Administration (FDA), marking a milestone for the company’s entry into the global vaccine market. The submission follows promising preclinical data and positions AIM as a pioneer in mRNA shingles vaccine development,…
-
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), has accepted the New Drug Application (NDA) for ipilimumab, an anti-CTLA-4 monoclonal antibody (mAb), and granted it Priority Review designation. The application covers the drug’s use in combination with sintilimab as…
-
AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments
•
The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent developments involving DeepSeek technology have further amplified this transformation. As highlighted by policy updates and industry trends, AI-powered solutions are gaining momentum across various sectors of healthcare, from diagnostics to drug discovery. This article explores…
-
In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications
•
The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on improving efficiency and accessibility in healthcare services. This policy reform targets three key stakeholders: designated medical institutions, pharmaceutical companies, and insured individuals, introducing six major service initiatives. Below is a detailed analysis of the reforms,…
-
State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms
•
The State Council has released a second draft proposal outlining measures to support the high-quality development of innovative drugs through medical insurance reforms. The document emphasizes the establishment of innovative drug investment funds, self-assessment mechanisms for drug pricing, and enhanced real-world research support. Key Proposals NRDL and Drug ListingThe draft…
-
Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing by expansion (SBX) technology, marking a significant advancement in next-generation sequencing (NGS). Technology OverviewSBX integrates innovative sensor modules to provide ultra-fast and high-throughput sequencing solutions. The technology is designed with broad flexibility and scalability, making…
-
Shanghai Issues Legal Guidebook for Innovative Drug Marketing
•
The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative drug marketing to pharmaceutical companies. The guidebook provides recommendations on commercial promotion, academic exchanges, transparent pricing, distributor management, and risk prevention. Key Provisions BackgroundThe guidebook was developed following a July 2024 research visit by the…
-
China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation
•
The Chinese government has released a set of opinions detailing the establishment of a new drug price formation mechanism by 2027, aiming to reduce financing costs for the innovative drug industry and support pharmaceutical innovation. Insurance Fund RoleThe document encourages commercial insurance companies to establish or clarify existing investment funds…
-
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced that the Ministry of Health, Labour and Welfare of Japan has approved Tecentriq (atezolizumab) for the treatment of unresectable alveolar soft part sarcoma. This marks the first approval of an immune…
-
GSK’s Nucala Receives NMPA Review for COPD Treatment
•
GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has accepted another indication approval filing for its anti-interleukin-15 (IL-15) biologic Nucala (mepolizumab) for review. The UK-based company is seeking approval for the drug’s use as an add-on maintenance treatment for patients with chronic obstructive pulmonary…
